Mast Therapeutics Changes Its Name In Hopes Of A Fresh Start
This article was originally published in The Pink Sheet Daily
Executive Summary
Formerly called Adventrx, the company says the name Mast better reflects its current strategy, which includes a focus on a Phase III asset for sickle cell disease. With a new name and a late-stage trial underway, management is hoping to persuade skeptical investors to take a second look.
You may also be interested in...
EPIC Fail For Mast Therapeutics’ Lead Drug Sends Shares Into Freefall
Shares in Mast Therapeutics dropped by more than 80% upon news that a Phase III trial of its lead product vepoloxamer in sickle cell disease had failed.
Mast Accelerates Enrollment In Pivotal Sickle Cell Study Of MST-188
With enrollment finally ramping up in trial open to older patients, Mast Therapeutics envisions a broad labeling horizon for MST-188, after a very long development road.
Mast Accelerates Enrollment In Pivotal Sickle Cell Study Of MST-188
With enrollment finally ramping up in trial open to older patients, Mast Therapeutics envisions a broad labeling horizon for MST-188, after a very long development road.